

**Access to Vaccines:  
Where are we,  
Why are we there,  
Where do we need to get to ?**


**Martin Friede**

Initiative for Vaccine Research




**World Health  
Organization**

# Vaccines work, but vaccine preventable diseases are still a significant cause of under-5 mortality




Source: Rota: Preliminary data (US Centers for Disease control), Hib and PCV: John's Hopkins University, other causes: WHO - Global Health Observatory

# Inequities in coverage



# Children in many countries still don't benefit from all recommended vaccines




Source: WHO/UNICEF Estimates of National Immunization Coverage, July 2017

4 | WIPO Vaccine Access 2017.


# The issues

- Numerous infectious diseases for which no vaccines yet available
- Available vaccine access inequitable – multiple reasons
  - Global capacity
  - Lack of competition
  - Affordability
  - Evidence
  - Procurement
  - Distribution
  - ....


# Holistic view of Access



# Innovation of new vaccines







# More researchers, more patents..



- Patents on vaccines per year 1900-2015




# Vaccine funding by year and sector





# Patents on TB, malaria, HIV , RSV, Dengue


## All patentees compared to 'big pharma'




# Effect on Business Models




# Effect of 'Frivolous' patents...



# Development Manufacture and Approval




# Economy of Scale




# A Holistic View of Access

**Evidence !**  
**Effectiveness, impact**  
**Delays !**




# Procurement





# Procurement




# Distribution and Administration




# Novel Vaccine Delivery Technologies

- Easier to transport (no cold chain, light weight)
- Easier to administer (no needle)
- Fewer administrations
- **BUT..... New formulations cost more !!**
  - Is the added cost worth the ease of delivery and administration ?


# Total Systems Effectiveness




Hypothetical country....



# Evaluation and Need



# Holistic view of Access



# The current downstream challenges

## Inadequate systems

- Trained human resources
- Vaccine supply chains
- Information systems

## Vaccine supply & price

- Availability
- Financing
- Pricing & procurement

## Reaching the “5<sup>th</sup> child”

- Unregistered & migrant populations
- Failure of integration: missed opportunities
- Conflicts and crisis
- Hesitancy and refusals

# Solutions exist: the challenge is to scale them up

## Inadequate systems

- Norms and standards; capacity strengthening
- Innovations in supply chain technology and design
- A systematic approach to strengthening information systems

## Vaccine supply & price

- Improving vaccine supply intelligence
- Vaccine pricing transparency and procurement support
- Improved costing and budgeting tools

## Reaching the “5<sup>th</sup> child”

- Mapping missed populations and improved microplanning
- Reducing missed opportunities
- Guidelines and support for vaccination in humanitarian emergencies
- Addressing hesitancy and refusals





World Health  
Organization

**Thank  
you**